当前位置: X-MOL 学术Appl. Neuropsychol. Child › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH) versus atomoxetine on executive function improvement and clinical effectiveness in ADHD: A randomized controlled trial
Applied Neuropsychology: Child ( IF 1.4 ) Pub Date : 2020-08-06 , DOI: 10.1080/21622965.2020.1796667
Yasemin Taş Torun 1 , Yasemen Işik Taner 1 , Esra Güney 1 , Elvan İseri 1
Affiliation  

Abstract

Objectives

The aim of this study to compare the clinic efficacy and effects of osmotic release oral system-methylphenidate and atomoxetine on executive function in children and adolescents with attention deficit hyperactivity disorder by a open-label, prospective, randomized controlled trial.

Methods

The study was performed by 95 cases between ages 6 and 12 years who were diagnosed as attention-deficit/hyperactivity disorder (ADHD) and also 40 control individuals. In this study, Conners’ Teacher Rating Scale (CTRS) was used in order to evaluate the efficacy of the treatment. Executive functions were assessed by the performance-based neuropsychological tests and ecological behavioral rating scales. Stroop test, cancellation test, and serial digit learning test were applied to performance based neuropsychological tests. Behavior Rating Inventory of Executive Function tests (BRIEFs) were used as behavioral assessment scales.

Results

Among the ADHD groups, a reduction of over 40% in the CTRS subtest scores used to evaluate the efficacy of the treatment was considered to be an improvement, and no significant difference was found for both drugs. Both Osmotic Release Oral System-Methylphenidate Hydrochloride (OROS-MPH) and atomoxetine (ATX) significantly improved scores in neuropsychological tests.

Conclusion

Atomoxetine and OROS-MPH treatments have shown similar efficacy in clinical recovery and improvement on executive functions. However, disturbances in executive functions observed in children with ADHD are persistent despite treatment, when compared with the control group.



中文翻译:

渗透释放口服系统 - 哌醋甲酯 (OROS-MPH) 与托莫西汀对 ADHD 执行功能改善和临床有效性的影响:一项随机对照试验

摘要

目标

本研究的目的是通过一项开放标签、前瞻性、随机对照试验,比较渗透释放口服系统 - 哌醋甲酯和托莫西汀对患有注意力缺陷多动障碍的儿童和青少年执行功能的临床疗效和影响。

方法

该研究由 95 名 6 至 12 岁被诊断为注意力缺陷/多动障碍 (ADHD) 的病例以及 40 名对照者进行。在本研究中,使用康纳斯教师评定量表 (CTRS) 来评估治疗效果。通过基于表现的神经心理学测试和生态行为评定量表评估执行功能。Stroop 测试、取消测试和序列数字学习测试被应用于基于性能的神经心理学测试。执行功能测试的行为评定量表(BRIEFs)被用作行为评估量表。

结果

在 ADHD 组中,用于评估治疗效果的 CTRS 分测验分数降低 40% 以上被认为是一种改善,两种药物没有发现显着差异。渗透释放口服系统-盐酸哌醋甲酯 (OROS-MPH) 和托莫西汀 (ATX) 均显着提高了神经心理学测试的分数。

结论

阿托莫西汀和 OROS-MPH 治疗在临床恢复和改善执行功能方面显示出相似的功效。然而,与对照组相比,尽管接受了治疗,但在 ADHD 儿童中观察到的执行功能障碍仍然存在。

更新日期:2020-08-06
down
wechat
bug